Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with...
-
Event titled “BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the...
-
BASEL, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety...
-
BASEL, Switzerland, March 31, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the...
-
BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy dataAlpibectir:...
-
BASEL, Switzerland, Oct. 22, 2024 (GLOBE NEWSWIRE) -- RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive fundingBioVersys taps into key expertise of the...
-
BV100 Phase 2 preliminary results suggest BV100 is generally safe and well tolerated and showed strong initial signs of efficacy in VABP patientsStrategic investment from GIBF and launch of...
-
BASEL, Switzerland, Sept. 24, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for...
-
BASEL, Switzerland, Sept. 11, 2024 (GLOBE NEWSWIRE) -- GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3...
-
BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- CF AMR Syndicate awarded BioVersys up to £ 500,000 to support project addressing resistant non-tubercular mycobacteria (NTM) lung infections...